Last mentioned: Mar 13, 2026
Josh Brown argues that biotech growth stocks are uniquely positioned to withstand the disruption risks currently de-rating the software and services sectors. By leveraging AI to accelerate discovery while maintaining regulatory and patent moats, the sector offers a rare combination of high growth and structural stability.
Financial commentator Josh Brown argues that biotech growth stocks possess a unique immunity to the disruption risks currently plaguing the technology sector. Unlike software, biotech's value is anchored in biological intellectual property and rigorous regulatory pathways that AI enhances rather than replaces.
Market commentator Josh Brown identifies biotechnology as a unique growth sector shielded from the deflationary pressures of artificial intelligence. Unlike software, biotech's regulatory and physical barriers create a durable moat that AI accelerates rather than disrupts.